Citadel Advisors
ONCR

Citadel Advisors’s Oncorus, Inc. ONCR Stock Holding History

Citadel Advisors’s Portfolio ONCR Stock Details ONCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$69 – 15633
2023
Q1 		$69 Sell
200
-500
-71% -$187 ﹤0.01% 14600
2022
Q4 		$177 Buy
+700
New +$398 ﹤0.01% 14737

Other funds holding ONCR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $328M AUM 19.81% 1-Year Est. Return

Citadel Advisors's ONCR Position: Q2 2023 in Review

Citadel Advisors sold out of Oncorus, Inc. (ONCR) in Q2 2023, closing a stake of 25,999 shares — an estimated $8.95K sold.

Citadel Advisors first reported a position in ONCR in Q4 2020 and held it in 10 quarters. The position peaked at $60.8M in Q4 2020. 4 funds tracked by Wall St. Rank hold ONCR as of Q2 2023.

  • Citadel Advisors reported no remaining Oncorus, Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 25,999 Oncorus, Inc. shares in Q2 2023, an estimated $8.95K.
  • Citadel Advisors first reported a position in Oncorus, Inc. in Q4 2020 and held it in 10 quarters.
  • Citadel Advisors's Oncorus, Inc. position peaked at $60.8M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Oncorus, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.